Find a Doctor

HL
Areas of Expertise

Heinz-josef D. Lenz

Usc Care Medical Group Inc
Oncology, Internal Medicine
Male
Practicing approx. 36 years

Bio

Heinz-josef Lenz is an Oncologist and an Internal Medicine specialist in Los Angeles, California. He has been an author on 322 peer reviewed articles and participated in 29 clinical trials in the past 15 years. He is licensed to treat patients in CA.

Areas of Expertise

Contact

1441 Eastlake Ave.
Nor 8302e
Los Angeles, CA 90033, US

323-865-3105

Latest Advances

Latest Advance
Study
  • Condition: Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
  • Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
  • Treatment Used: Durvalumab and Tremelimumab Alone or in Combination
  • Number of Patients: 113
  • Published —
The study researched the outcomes of Durvalumab and Tremelimumab alone or in combination for advanced gastric and gastroesophageal junction adenocarcinoma.
Latest Advance
Study
  • Condition: Advanced or Metastatic Colorectal Cancer
  • Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
  • Treatment Used: 25-hydroxyvitamin D
  • Number of Patients: 1041
  • Published —
This study evaluated the influence of vitamin D status on disease progression and patient survival for patients with advanced or metastatic colorectal cancer.
Latest Advance
Study
  • Condition: Metastatic Colorectal Cancer
  • Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • Treatment Used: Physical Activity
  • Number of Patients: 1218
  • Published —
The study researched physical activity on the survival and progression of metastatic colorectal cancer.
Latest Advance
Study
  • Condition: Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer (mCRC)
  • Journal: The oncologist
  • Treatment Used: Nivolumab plus Low-Dose Ipilimumab
  • Number of Patients: 119
  • Published —
This study presented in-depth safety and additional effectiveness outcomes for for previously treated microsatellite instability-high and/or mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC).
Latest Advance
Study
  • Condition: Advanced Solid Tumors
  • Journal: International journal of cancer
  • Treatment Used: Regorafenib with Cetuximab
  • Number of Patients: 42
  • Published —
In this study, researchers evaluated the safety of regorafenib with cetuximab for the treatment of advanced solid tumors.
Latest Advance
Study
  • Condition: Metastatic Colorectal Cancer
  • Journal: The oncologist
  • Treatment Used: FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab
  • Number of Patients: 280
  • Published —
The study compared the safety and effectiveness of FOLFOXIRI-Bevacizumab versus FOLFOX-Bevacizumab for treating metastatic colorectal cancer.
Latest Advance
Study
  • Condition: Untreated Advanced or metastatic colorectal cancer (CRC)
  • Journal: American journal of clinical oncology
  • Treatment Used: Celecoxib with Irinotecan, 5-fluorouracil, and leucovorin (IFL)
  • Number of Patients: 47
  • Published —
This study investigated the addition of celecoxib, a selective COX-2 inhibitor, to the irinotecan, 5-fluorouracil, and leucovorin (IFL) regimen for patients with previously untreated metastatic CRC.
Latest Advance
Study
  • Condition: Patients with Advanced Solid Tumors
  • Journal: Investigational new drugs
  • Treatment Used: MK-8033
  • Number of Patients: 47
  • Published —
This study evaluated the safety and effects of of proton-pump inhibitors on MK-8033 absorption in the treatment of patients with advanced solid tumors.

Clinical Trials

Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1
  • Intervention Type: Drug
  • Participants: 30
  • Start Date: July 30, 2020
First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Drug
  • Participants: 144
  • Start Date: May 1, 2020
A Phase II Randomized Double-Blind Trial of Baricitinib or Placebo Combined With Antiviral Therapy in Patients With Moderate and Severe COVID-19
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Other, Biological, Drug
  • Participants: 120
  • Start Date: April 24, 2020
PULSE: A Randomized, Phase II Open Label Study of PanitUmumab RechaLlenge Versus Standard Therapy After Progression on Anti-EGFR Therapy in Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
Clinical Trial
  • Status: Recruiting
  • Intervention Type: Other
  • Participants: 500
  • Start Date: April 22, 2020
COLOMATE: Colorectal Cancer Liquid Biopsy Screening Protocol for Molecularly Assigned Therapy
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Biological, Drug
  • Participants: 124
  • Start Date: March 3, 2020
A Randomized Phase II Study of Regorafenib Followed by Anti-EGFR Monoclonal Antibody Therapy Versus the Reverse Sequencing for Metastatic Colorectal Cancer Patients Previously Treated With Fluoropyrimidine, Oxaliplatin and Irinotecan (REVERCE II)
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1/Phase 2
  • Intervention Type: Drug, Biological
  • Participants: 45
  • Start Date: January 30, 2020
A Phase Ib/II Study of Guadecitabine (SGI-110) Plus Nivolumab in Refractory CIMP+ Metastatic Colorectal Cancer
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1
  • Intervention Type: Biological
  • Participants: 128
  • Start Date: January 23, 2020
A Multicentre, Open-label, Non-randomised First in Human Study of NG-641, an Oncolytic Transgene Expressing Adenoviral Vector, in Patients With Metastatic or Advanced Epithelial Tumours (STAR)
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 3
  • Intervention Type: Other, Drug, Dietary Supplement
  • Participants: 400
  • Start Date: September 30, 2019
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1/Phase 2
  • Intervention Type: Drug
  • Participants: 32
  • Start Date: July 22, 2019
An Open-Label, Multicenter, Non-Randomized, Dose-Confirmation and Cohort-Expansion Phase 1b Study to Evaluate the Safety, Tolerability, and Anti-Tumor Activity of ATP128, With or Without BI 754091, in Patients With Stage IV Colorectal Cancer
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1/Phase 2
  • Intervention Type: Biological, Drug
  • Participants: 64
  • Start Date: March 28, 2019
A Phase I Study of Anetumab Ravtansine in Combination With Either Anti-PD-1 Antibody, or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Drug
  • Participants: 15
  • Start Date: January 30, 2019
A Phase 2 Study of Savolitinib in Subjects With MET Amplified Metastatic Colorectal Cancer
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Drug
  • Participants: 145
  • Start Date: March 30, 2018
A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Device, Biological, Other, Drug
  • Participants: 130
  • Start Date: October 9, 2017
S1613, A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 Amplification
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 3
  • Intervention Type: Other, Drug
  • Participants: 700
  • Start Date: September 12, 2017
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Drug
  • Participants: 115
  • Start Date: June 23, 2017
MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Procedure, Biological
  • Participants: 818
  • Start Date: January 13, 2017
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

All Publications
View All

Publication
Study
  • Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • Published —
Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406).
Publication
Study
  • Journal: JCO oncology practice
  • Published —
All You Need to Know About DPYD Genetic Testing for Patients Treated With Fluorouracil and Capecitabine: A Practitioner-Friendly Guide.

Contact

1441 Eastlake Ave.
Nor 8302e
Los Angeles, CA 90033, US

323-865-3105

Affiliations

  • Usc Kenneth Norris Jr Cancer Hospital
  • Lac+usc Medical Center
  • Keck Hospital Of Usc

Credentials

  • Licenses
    Internal Medicine in CA
  • Board Certifications
    Medical Oncology
    Hematology/oncology

Insurance

Contact them to find out if they accept your insurance plan.